
ABBV
AbbVie Inc.
Pharmaceutical company with focus on immunology and virology. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
3
$18.98M
Insider Sales
16
$99.93M
Total Volume
$118.92M
32 transactions
Net Activity
$80.95M
Net selling
Sentiment Rating
Strong AccumulationCEO Conviction Index
High Conviction Accumulation
Key Drivers
- •Heavy distribution: sales represent 84% of total transaction value.
- •Cluster buying: 3 unique insiders purchased shares, showing strong alignment.
- •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
- •CFO buying activity detected. Statistical studies show CFO purchases have high predictive power due to their direct visibility into balance sheet details.
- •Ultra-high accumulation: total purchase value exceeds $10M.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
$24.29M total
Gonzalez Richard A
Dir
$20.26M total
Siatis Perry C
EVP, GC, SECRETARY
$16.49M total
Donoghoe Nicholas
EVP, CHIEF BUS, STRAT OFFICER
$10.82M total
Richmond Timothy J.
EVP, CHRO
$10.54M total
Quick Actions
ABBV has an insider buy conviction of 16%, compared to the Pharmaceuticals sector buy average of 0%. ABBV ranks #1 in insider activity out of 1 tracked companies in its industry.
Over the last 90 days, corporate insiders at AbbVie Inc. (ABBV) engaged in a total of 32 transactions reported via SEC Form 4 filings. Among these, 3 were open-market purchases and 16 were sales. The total volume of insider trading reached $118.92M.
The net insider activity for ABBV shows a net selling bias of $80.95M. This activity represents a 16% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Gonzalez Richard A (Dir), who traded 98.6K shares valued at $20.26M on Feb 28, 2025.
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?
AbbVie (ABBV) Stock Climbs As Q3 Earnings Fuel Growth Case
AbbVie inks up to $2.54B bispecific cancer drug deal with DISCO Pharma
AbbVie (ABBV) Stock Still Looks Cheap On Its 197% Five Year Run
Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy.
AbbVie (ABBV) Stock May Be 41% Undervalued Following JUVMO Approval
Explore Peers in Drug Manufacturers
Compare insider activity and sentiment scores across similar organizations.
FAQs About AbbVie Inc. Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ABBV.

